What Could Go Wrong At Gilead From Here?
Gilead Sciences (GILD) reported 16% sales growth excluding Veklury in Q3 2026. The stock rose 47.4% since Oct. 2025. CMS set Biktarvy's Medicare price at $2,600, 38% below list price, expected to reduce 2028 revenue by $1.5B. Biktarvy accounted for $14.3B of 2025 sales. GILD stock trades at 6.8x sales, near its 1-year high.
How this was made
The 30-second read
Why it matters
The $2,600 per 30‑day supply price is about 38% below list, translating to an estimated $1.5 bn revenue hit in 2028, roughly 10% of FY‑25 Biktarvy sales.
Market read
The price reduction is a material regulatory event for Gilead, likely to depress its stock ahead of the February 2027 earnings.
What to watch
Potential cost‑offsets from higher margins on other products and upcoming pipeline launches.
Background
Gilead disclosed during its Q3 2026 earnings call that CMS set a lower Medicare price for Biktarvy, its top‑selling HIV drug.
Ticker impact
CMS set Medicare price for Biktarvy 38% below list, projecting $1.5 bn revenue loss in 2028.
likely pressure as the market prices in the $1.5 bn revenue hit.
A large, disclosed Medicare price reduction directly hits Gilead's flagship HIV drug, a material revenue driver.
Market effects
May weigh on other HIV‑focused biotech stocks as Medicare pricing scrutiny intensifies.
U.S. healthcare sector could see modest downside pressure.
Limited to U.S. investors; global markets unlikely to be materially affected.
Counterpoint
If Biktarvy volume sustains and other HIV products grow, the impact may be muted.
Key entities
- companyGilead Sciences
US‑listed biopharma (ticker GILD) facing Medicare price cut.
- government_agencyCMS
Centers for Medicare & Medicaid Services setting drug price.
